Pegfilgrastim versus filgrastim for chemo-mobilized stem cell collection in multiple myeloma: A retrospective real-world study
Authors:
Open Access
- 26 May 2026
- journal article
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 48, 101263
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastimAnnals of Hematology, 2024
- Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantationAnnals of Hematology, 2023
- Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myelomaAnnals of Hematology, 2020
- A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplantAnnals of Hematology, 2019
- Pegfilgrastim: More Cost Effective and Equally Efficacious Option as Compared to Filgrastim in Autologous Stem Cell TransplantIndian Journal of Hematology and Blood Transfusion, 2018
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trialThe Lancet, 2017
- Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating FactorBioDrugs, 2015
- International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaThe Lancet Oncology, 2014
- Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and RecommendationsTransplantation and Cellular Therapy, 2014
- A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humansExperimental Hematology, 1999